Capstone Investment Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-6,100
| Closed | -$520K | – | 1668 |
|
|
2025
Q4 | $520K | Sell |
6,100
-3,200
| -34% | -$263K | ﹤0.01% | 1136 |
|
|
2025
Q3 | $723K | Buy |
9,300
+1,600
| +21% | +$125K | ﹤0.01% | 1157 |
|
|
2025
Q2 | $602K | Sell |
7,700
-15,000
| -66% | -$1.12M | ﹤0.01% | 1059 |
|
|
2025
Q1 | $1.65M | Sell |
22,700
-4,600
| -17% | -$329K | ﹤0.01% | 739 |
|
|
2024
Q4 | $2.02M | Buy |
27,300
+7,500
| +38% | +$525K | ﹤0.01% | 849 |
|
|
2024
Q3 | $1.31M | Buy |
19,800
+5,300
| +37% | +$385K | ﹤0.01% | 877 |
|
|
2024
Q2 | $1.34M | Buy |
14,500
+4,600
| +46% | +$407K | ﹤0.01% | 867 |
|
|
2024
Q1 | $946K | Sell |
9,900
-17,700
| -64% | -$1.49M | ﹤0.01% | 1184 |
|
|
2023
Q4 | $2.1M | Buy |
27,600
+7,500
| +37% | +$522K | 0.01% | 782 |
|
|
2023
Q3 | $1.39M | Buy |
20,100
+400
| +2% | +$32.1K | 0.01% | 860 |
|
|
2023
Q2 | $1.86M | Hold |
19,700
| – | – | 0.01% | 660 |
|
|
2023
Q1 | $1.63M | Sell |
19,700
-9,200
| -32% | -$723K | 0.01% | 649 |
|
|
2022
Q4 | $2.16M | Buy |
28,900
+2,700
| +10% | +$208K | 0.02% | 683 |
|
|
2022
Q3 | $2.17M | Buy |
26,200
+2,100
| +9% | +$202K | 0.01% | 723 |
|
|
2022
Q2 | $2.29M | Sell |
24,100
-17,000
| -41% | -$1.76M | 0.01% | 708 |
|
|
2022
Q1 | $4.84M | Sell |
41,100
-15,900
| -28% | -$1.78M | 0.01% | 719 |
|
|
2021
Q4 | $7.38M | Sell |
57,000
-2,800
| -5% | -$327K | 0.01% | 708 |
|
|
2021
Q3 | $6.77M | Buy |
59,800
+5,300
| +10% | +$605K | 0.01% | 756 |
|
|
2021
Q2 | $5.64M | Buy |
54,500
+14,400
| +36% | +$1.36M | 0.01% | 701 |
|
|
2021
Q1 | $3.35M | Sell |
40,100
-60,300
| -60% | -$5.1M | 0.01% | 761 |
|
|
2020
Q4 | $9.16M | Buy |
100,400
+1,800
| +2% | +$149K | 0.03% | 422 |
|
|
2020
Q3 | $7.87M | Buy |
98,600
+12,700
| +15% | +$991K | 0.04% | 382 |
|
|
2020
Q2 | $5.94M | Buy |
85,900
+26,200
| +44% | +$1.86M | 0.04% | 377 |
|
|
2020
Q1 | $3.75M | Sell |
59,700
-47,700
| -44% | -$3.44M | 0.06% | 350 |
|
|
2019
Q4 | $8.35M | Buy |
107,400
+27,600
| +35% | +$2.16M | 0.05% | 406 |
|
|
2019
Q3 | $5.85M | Buy |
79,800
+19,500
| +32% | +$1.37M | 0.04% | 396 |
|
|
2019
Q2 | $3.71M | Buy |
60,300
+28,500
| +90% | +$1.72M | 0.03% | 551 |
|
|
2019
Q1 | $2.03M | Buy |
31,800
+22,200
| +231% | +$1.27M | 0.02% | 602 |
|
|
2018
Q4 | $490K | Sell |
9,600
-1,500
| -14% | -$75.9K | 0.01% | 819 |
|
|
2018
Q3 | $644K | Buy |
+11,100
| New | +$543K | 0.01% | 726 |
|
Other funds holding EW
Capstone Investment Advisors's EW Position: Q2 2026 in Review
Capstone Investment Advisors sold out of Edwards Lifesciences (EW) in Q2 2026, closing a stake of 4,024 shares — an estimated $337K sold.
Capstone Investment Advisors first reported a position in EW in Q4 2015 and held it in 31 quarters. The position peaked at $4.19M in Q3 2022. 1,337 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- Capstone Investment Advisors reported no remaining Edwards Lifesciences position as of Q2 2026 after selling out during the quarter.
- Capstone Investment Advisors sold 4,024 Edwards Lifesciences shares in Q2 2026, an estimated $337K.
- Capstone Investment Advisors first reported a position in Edwards Lifesciences in Q4 2015 and held it in 31 quarters.
- Capstone Investment Advisors's Edwards Lifesciences position peaked at $4.19M in Q3 2022.
- 1,337 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.